Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?

According to the ejection fraction, patients with heart failure may be divided into two different groups: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More im...

Full description

Saved in:
Bibliographic Details
Main Authors: Jia Li, Peter Moritz Becher, Stefan Blankenberg, Dirk Westermann
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2013/130724
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832553934794784768
author Jia Li
Peter Moritz Becher
Stefan Blankenberg
Dirk Westermann
author_facet Jia Li
Peter Moritz Becher
Stefan Blankenberg
Dirk Westermann
author_sort Jia Li
collection DOAJ
description According to the ejection fraction, patients with heart failure may be divided into two different groups: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More importantly, despite decline in mortality after treatment in regard to current guideline in patients with heart failure with reduced ejection fraction, there are still no trials resulting in improved outcome in patients with heart failure with preserved ejection fraction so far. Thus, novel pathophysiological mechanisms are under development, and other new viewpoints, such as multiple comorbidities resulting in increased non-cardiac deaths in patients with heart failure and preserved ejection fraction, were presented recently. In this review, we will focus on the tested as well as the promising therapeutic options that are currently studied in patients with heart failure with preserved ejection fraction, along with a brief discussion of pathophysiological mechanisms and diagnostic options that are helpful to increase our understanding of novel therapeutic strategies.
format Article
id doaj-art-317b791511e04905ab246b98326ef367
institution Kabale University
issn 2090-8016
2090-0597
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-317b791511e04905ab246b98326ef3672025-02-03T05:52:41ZengWileyCardiology Research and Practice2090-80162090-05972013-01-01201310.1155/2013/130724130724Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?Jia Li0Peter Moritz Becher1Stefan Blankenberg2Dirk Westermann3Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, GermanyDepartment of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, GermanyDepartment of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, GermanyDepartment of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, GermanyAccording to the ejection fraction, patients with heart failure may be divided into two different groups: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More importantly, despite decline in mortality after treatment in regard to current guideline in patients with heart failure with reduced ejection fraction, there are still no trials resulting in improved outcome in patients with heart failure with preserved ejection fraction so far. Thus, novel pathophysiological mechanisms are under development, and other new viewpoints, such as multiple comorbidities resulting in increased non-cardiac deaths in patients with heart failure and preserved ejection fraction, were presented recently. In this review, we will focus on the tested as well as the promising therapeutic options that are currently studied in patients with heart failure with preserved ejection fraction, along with a brief discussion of pathophysiological mechanisms and diagnostic options that are helpful to increase our understanding of novel therapeutic strategies.http://dx.doi.org/10.1155/2013/130724
spellingShingle Jia Li
Peter Moritz Becher
Stefan Blankenberg
Dirk Westermann
Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
Cardiology Research and Practice
title Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
title_full Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
title_fullStr Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
title_full_unstemmed Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
title_short Current Treatment of Heart Failure with Preserved Ejection Fraction: Should We Add Life to the Remaining Years or Add Years to the Remaining Life?
title_sort current treatment of heart failure with preserved ejection fraction should we add life to the remaining years or add years to the remaining life
url http://dx.doi.org/10.1155/2013/130724
work_keys_str_mv AT jiali currenttreatmentofheartfailurewithpreservedejectionfractionshouldweaddlifetotheremainingyearsoraddyearstotheremaininglife
AT petermoritzbecher currenttreatmentofheartfailurewithpreservedejectionfractionshouldweaddlifetotheremainingyearsoraddyearstotheremaininglife
AT stefanblankenberg currenttreatmentofheartfailurewithpreservedejectionfractionshouldweaddlifetotheremainingyearsoraddyearstotheremaininglife
AT dirkwestermann currenttreatmentofheartfailurewithpreservedejectionfractionshouldweaddlifetotheremainingyearsoraddyearstotheremaininglife